Non-hodgkin's%20lymphoma News

News

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

SC on par with IV rituximab in CD20+ diffuse large B-cell lymphoma

Stephen Padilla, 20230822120000

In patients with previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL), treatment with subcutaneous (SC) rituximab is not inferior to intravenous (IV) rituximab in terms of serum trough levels, efficacy, and tolerability, as shown in a study presented at EHA 2023.

Geriatrician Dr Carol Tan speaks about the dangers of polypharmacy in elderly patients

Does polypharmacy affect survival in older patients with haematological malignancy?

Stephen Padilla, 20230710120000

Polypharmacy does not appear to result in poorer treatment response and survival in older patients with different haematological malignancies, as shown in a study presented at the recent EHA 2023.

Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma

Stephen Padilla, 20230515120000

Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.

Anthracycline treatment for cancer linked to increased risk of congestive heart failure

20230207150000

The use of anthracyclines in the treatment of cancer appears to carry a twofold risk of congestive heart failure, according to a study.

$PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib$

PFS in relapsed/refractory CLL/SLL: Zanubrutinib triumphs over ibrutinib

Roshini Claire Anthony, 20230115100001

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.

Updated long-term data AUGMENT R2 efficacy for R/R iNHL

Audrey Abella, 20221222100000

In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study

Christina Lau, 20221214042231

First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64^th American Society of Hematology (ASH) Annual Meeting and Exposition.

Original New Drug Application Approvals by US FDA (16 - 30 November 2022)

20221205022722

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

Jairia Dela Cruz, 20220803140000

Photodynamic therapy using topically applied hypericin 0.25% is effective against early-stage patch and plaque lesions in patients with mycosis fungoides−cutaneous T-cell lymphoma, while having a favourable safety profile, as shown in the phase III FLASH trial.

Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma

Roshini Claire Anthony, 20220630180001

A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.

New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations

31 Mar 2021

At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT^®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.

Immunotherapy sparks hope for paediatric ALL

Audrey Abella, 14 Oct 2020

Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).